In this study, we analyzed the changes in tumor markers, both AFP and DCP, which were linked to the tumor evaluation decision in RECIST, especially at the time of PD evaluation, with a significant increase in AFP and DCP after one month, suggesting that they may be useful in determining early efficacy. This evidence concerns the gene ACE and neoplasm.